Cart
sales@molnova.com
Survodutide
CAS No. 2805997-46-8
Survodutide( —— )
Catalog No. M36653 CAS No. 2805997-46-8
Survodutide (BI 456906) is a dual agonist of glucagon and glucagon-like peptide 1 (GLP-1) receptors (GLP Receptor) that reduces body weight in HbA1c16 diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 161 | Get Quote |
|
| 5MG | 217 | Get Quote |
|
| 10MG | 330 | Get Quote |
|
| 25MG | 531 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSurvodutide
-
NoteResearch use only, not for human use.
-
Brief DescriptionSurvodutide (BI 456906) is a dual agonist of glucagon and glucagon-like peptide 1 (GLP-1) receptors (GLP Receptor) that reduces body weight in HbA1c16 diabetes.
-
DescriptionSurvodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.
-
In Vitro——
-
In VivoAnimal Model:Male C57BL6/J mice pre-fed with a 60% HFD (22 weeks)Dosage:3, 10, 20, 30 nmol/kg Administration:SC; daily; 30 days Result:Dose-dependently reduced bodyweight from baseline by up to 32% at Day 28 at a dose of 30 nmol/kg.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetGlucagon Receptor
-
RecptorGlucagon Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2805997-46-8
-
Formula Weight4231.62
-
Molecular FormulaC192H289N47O61
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (23.63 mM; Ultrasonic )
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Bay 55-9837
Selective VPAC2 receptor agonist (EC50 values are 0.4, 100 and >1000 nM for VPAC2, VPAC1 and PAC1, respectively in a cAMP accumulation assay; IC50 values are 60, 8700 and >10000 nM for VPAC2, VPAC1 and PAC1, respectively in a competition binding assay). Stimulates glucose-dependent insulin secretion in isolated human pancreatic islets. Reduces HIV-1 viral replication and shows cooperative effects when given in conjunction with VPAC1 agonists.
-
HAEGT
HAEGT is the first N-terminal 1-5 residues of GLP-1 peptide.
-
PF-06882961
PF-06882961 is an orally bioavailable glucagon-like peptide-1 receptor (GLP-1R) agonist. PF-06882961 shows mild to moderate damage to the heart, moderate to severe effects on the thymus gland (which helps with managing infection), mild to moderate stomach ulcers at the highest dose level given in the rat.
